Faeth reports positive preliminary Phase 2 results for PIKTOR with paclitaxel in endometrial cancer
FROM THE WIRE · FINANCE.YAHOO.COM
Confirmed Objective Response Rate (ORR) of 33% in efficacy-evaluable patients (12 of 36), and a disease control rate (DCR) of 83% Among patients with a PIK3CA mutation, the confirmed ORR was 44% (7 of 16) Preliminary Kaplan-Meier estimated median progression-free survival (mPFS)…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive clinical data supporting advancement to Phase 3, relevant for the stock as a small-cap.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The confirmed objective response rate was 33% (12 of 36 evaluable patients).
- 02Preliminary estimated median progression-free survival was 7.4 months.
- 03The data support advancing PIKTOR into a Phase 3 registrational trial.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets